Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Whole Blood Transcript Clusters for Ischemic Stroke Detection
Case ID:
1935-100
Web Published:
7/11/2023
Provides a better method for diagnosing acute ischemic stroke. Background: Strokes result from reductions of blood flow to the brain and are second to coronary heart disease in terms of vascular disease incidence, morbidity, and mortality. About 83% of strokes are due to arterial vascular occlusion (ischemic stroke), and about 17% are due to vascular rupture (hemorrhagic stroke). Over the past 20 years, many scientific advances have been made in stroke diagnosis, treatment, and prevention; but important questions remain. Stroke diagnosis is inaccurate in up to 30% of patients, and it is not possible to reliably distinguish between ischemic and hemorrhagic stroke clinically. Clearly, a need exists for a panel of biomarkers associated with an increased risk of stroke. Technology Overview: This SUNY Downstate Health Sciences University technology provides biomarkers for the diagnosis and treatment of acute ischemic stroke. It also includes a quantitative assay method for accurately identifying the appropriate transcript number in a biological sample. This provides a method for identifying patients having an increased risk for developing acute ischemic stroke. For example, a biological sample can be obtained from the patient and used to determine the expression levels of at least three gene markers. The technology also provides a method for identifying agents useful for the treatment of acute ischemic stroke. Stage of Development Technology Readiness Level (TRL) 3 - Experimental proof of concept. Advantages:
More accurate diagnosis of stroke
Identifies patients with increased risk for developing acute ischemic stroke
Better distinguishing between ischemic stroke and hemorrhagic stroke
Applications: Identifying patients with increased risk for acute stroke. Intellectual Property Summary: This technology is covered by the patent
US 11021750 B2
, Biomarkers for Predicting Risk of Acute Ischemic Stroke and Methods of Use Thereof. Licensing Status: This technology is available for licensing and will be of value to any company or institution involved in diagnosing and treating acute stroke. This includes:
Manufacturers of medical test products
Hospitals
Rehabilitation facilities
https://suny.technologypublisher.com/files/sites/1935-100_adobestock_434607074.jpeg
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Whole_Blood_Transcript_Clust ers_for_Ischemic_Stroke_Detection
Keywords:
Bookmark this page
Download as PDF
For Information, Contact:
Andrew Scheinman
Business Development & Licensing Associate
The Research Foundation for The State University of New York
andrew.scheinman@rfsuny.org